CY1117562T1 - Τριαζολοπυριδινες ως αναστολεις φωσφοδιεστερασης για την θεραπεια δερματικων ασθενειων - Google Patents

Τριαζολοπυριδινες ως αναστολεις φωσφοδιεστερασης για την θεραπεια δερματικων ασθενειων

Info

Publication number
CY1117562T1
CY1117562T1 CY20161100373T CY161100373T CY1117562T1 CY 1117562 T1 CY1117562 T1 CY 1117562T1 CY 20161100373 T CY20161100373 T CY 20161100373T CY 161100373 T CY161100373 T CY 161100373T CY 1117562 T1 CY1117562 T1 CY 1117562T1
Authority
CY
Cyprus
Prior art keywords
treatment
triazolopyrides
phosphodesteration
inhibitors
skin diseases
Prior art date
Application number
CY20161100373T
Other languages
English (en)
Inventor
Simon Feldbæk Nielsen
Thomas Vifian
Anne Marie Horneman
Jesper Færgemann Lau
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of CY1117562T1 publication Critical patent/CY1117562T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μία ένωση σύμφωνα με τον τύπο I, όπου τα R1, R2 και Α είναι όπως ορίζονται στο παρόν, τα οποία εμφανίζουν ανασταλτική δραστικότητα PDE4 και μπορούν να χρησιμοποιηθούν στη θεραπεία των φλεγμονωδών νόσων ή αυτοάνοσων ασθενειών, ιδιαίτερα των φλεγμονωδών ή πολλαπλασιαστικών δερματικών παθήσεων.
CY20161100373T 2008-12-19 2016-05-06 Τριαζολοπυριδινες ως αναστολεις φωσφοδιεστερασης για την θεραπεια δερματικων ασθενειων CY1117562T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13944508P 2008-12-19 2008-12-19
EP09795687.4A EP2379548B1 (en) 2008-12-19 2009-12-18 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Publications (1)

Publication Number Publication Date
CY1117562T1 true CY1117562T1 (el) 2017-04-26

Family

ID=41693461

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100373T CY1117562T1 (el) 2008-12-19 2016-05-06 Τριαζολοπυριδινες ως αναστολεις φωσφοδιεστερασης για την θεραπεια δερματικων ασθενειων

Country Status (25)

Country Link
US (1) US8952162B2 (el)
EP (1) EP2379548B1 (el)
JP (2) JP5743901B2 (el)
KR (1) KR20110094355A (el)
CN (1) CN102317287B (el)
AU (1) AU2009328752B2 (el)
BR (1) BRPI0922452A2 (el)
CA (1) CA2747022A1 (el)
CY (1) CY1117562T1 (el)
DK (1) DK2379548T3 (el)
ES (1) ES2570769T3 (el)
HK (1) HK1165791A1 (el)
HR (1) HRP20160488T1 (el)
HU (1) HUE027770T2 (el)
IL (1) IL213570A (el)
MX (1) MX2011006428A (el)
NO (1) NO20110871A1 (el)
NZ (1) NZ593595A (el)
PL (1) PL2379548T3 (el)
RS (1) RS54752B1 (el)
RU (1) RU2544011C2 (el)
SG (1) SG172206A1 (el)
SI (1) SI2379548T1 (el)
WO (1) WO2010069322A1 (el)
ZA (1) ZA201104422B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI500614B (zh) 2009-06-05 2015-09-21 Cephalon Inc １，２，４－三唑並〔１，５ａ〕吡啶衍生物之製備和用途
SG178049A1 (en) 2009-07-17 2012-03-29 Japan Tobacco Inc Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
CA2785251A1 (en) 2009-12-22 2011-06-30 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
RU2559084C2 (ru) 2009-12-22 2015-08-10 Лео Фарма А/С Фармацевтическая композиция, включающая растворяющую смесь и производное или аналог витамина d
ES2523119T3 (es) 2009-12-22 2014-11-21 Leo Pharma A/S Nanocristales de monohidrato de calcipotriol
ES2711100T3 (es) * 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
EP2794603B1 (en) 2011-12-21 2016-06-15 Leo Pharma A/S [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors
CN104822392B (zh) * 2012-11-30 2017-09-08 利奥制药有限公司 抑制活化的t‑细胞中il‑22表达的方法
WO2014206903A1 (en) 2013-06-25 2014-12-31 Leo Pharma A/S METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
ES2935615T3 (es) 2017-12-15 2023-03-08 Union Therapeutics As Azetidina dihidrotienopiridinas sustituidas y su uso como inhibidores de la fosfodiesterasa
JP2021155336A (ja) * 2018-06-27 2021-10-07 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
AR114977A1 (es) 2018-06-27 2020-11-11 Meiji Seika Pharma Co Ltd Cristales de derivado de benzoxazol

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258775T3 (es) 1995-05-19 2006-09-01 Kyowa Hakko Kogyo Co., Ltd. Compuestos heterociclicos que contienen oxigeno.
AU4967697A (en) 1996-11-19 1998-06-10 Kyowa Hakko Kogyo Co. Ltd. Oxygenic heterocyclic compounds
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2007091597A (ja) 2005-09-27 2007-04-12 Kyorin Pharmaceut Co Ltd ピラゾロピリジン−４−イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤
US20090196284A1 (en) * 2006-06-28 2009-08-06 Nokia Siemens Networks Gmbh & Co.Kg Method for Providing an Emergency Call Service for VoIP Subscribers
US20100035756A1 (en) * 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
JP2008024599A (ja) 2006-07-18 2008-02-07 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体、それらを有効成分とするｐｄｅ阻害剤及び医薬
JP2008069144A (ja) 2006-08-17 2008-03-27 Kyorin Pharmaceut Co Ltd ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
ATE540037T1 (de) 2007-04-16 2012-01-15 Leo Pharma As Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
US20100160335A1 (en) 2007-06-19 2010-06-24 Kyorin Pharmaceutical Co., Ltd. Pyridazinone derivative and pde inhibitor containing the same as active ingredient
JPWO2008156102A1 (ja) * 2007-06-19 2010-08-26 杏林製薬株式会社 ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
JP2009040711A (ja) * 2007-08-08 2009-02-26 Kyorin Pharmaceut Co Ltd カルボスティリル誘導体及びそれらを有効成分とするｐｄｅ阻害剤
EP2348018A4 (en) 2008-09-25 2012-04-25 Kyorin Seiyaku Kk HETEROCYCLIC BIARYLIC DERIVATIVE AND PDE INHIBITOR COMPRISING THE SAME AS ACTIVE INGREDIENT
US20110224250A1 (en) 2008-10-09 2011-09-15 Yasushi Kohno Isoquinoline derivative, and pde inhibitor comprising same as active ingredient

Also Published As

Publication number Publication date
KR20110094355A (ko) 2011-08-23
WO2010069322A1 (en) 2010-06-24
ZA201104422B (en) 2012-09-26
JP2012512192A (ja) 2012-05-31
JP2015096535A (ja) 2015-05-21
RU2544011C2 (ru) 2015-03-10
BRPI0922452A2 (pt) 2015-12-15
HRP20160488T1 (hr) 2016-06-17
JP5743901B2 (ja) 2015-07-01
NO20110871A1 (no) 2011-09-19
CN102317287B (zh) 2014-10-08
IL213570A (en) 2015-10-29
MX2011006428A (es) 2011-07-28
DK2379548T3 (en) 2016-05-17
EP2379548A1 (en) 2011-10-26
NZ593595A (en) 2013-07-26
AU2009328752A1 (en) 2011-07-07
RS54752B1 (sr) 2016-10-31
US20120028974A1 (en) 2012-02-02
HK1165791A1 (en) 2012-10-12
CA2747022A1 (en) 2010-06-24
PL2379548T3 (pl) 2016-08-31
SI2379548T1 (sl) 2016-06-30
HUE027770T2 (en) 2016-11-28
AU2009328752B2 (en) 2015-07-16
SG172206A1 (en) 2011-07-28
US8952162B2 (en) 2015-02-10
CN102317287A (zh) 2012-01-11
EP2379548B1 (en) 2016-03-09
ES2570769T3 (es) 2016-05-20
IL213570A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
CY1117562T1 (el) Τριαζολοπυριδινες ως αναστολεις φωσφοδιεστερασης για την θεραπεια δερματικων ασθενειων
CY1124168T1 (el) Ετεροκυκλυλαμiνες ως αναστολεiς ρι3κ
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CY1120995T1 (el) Ετεροκυκλικη ενωση και χρηση αυτης
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1118740T1 (el) Ενωσεις αναστολης δραστικοτητας της ο-μεθυλτρανσφερασης κατεχολης
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
EA201201648A1 (ru) Стимуляторы sgc
CU24097B1 (es) Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas
EA201170521A1 (ru) Новые соединения
CR20150217A (es) Inhibidores de histona demetilasas
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
EA201170832A1 (ru) Пуриновые соединения
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
UY32730A (es) Inhibidores de cyp17
EA201171367A1 (ru) Винилиндазолильные соединения
PE20151023A1 (es) Triazolopirazinas
MX2010008198A (es) Inhibidores de cinasa de pirrolopirazina.
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MX336381B (es) Boronatos como inhibidores de arginasa.
HN2008000317A (es) Benzimidazoles sustituidos como inhibidores de cinasa
ZA201904522B (en) Heterocyclic inhibitors of mct4
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
CY1116984T1 (el) ΠΑΡΑΓΩΓΑ [1,2,3]ΤΡΙΑΖΟΛΟ[4,5-d]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ ΚΑΝΝΑΒΙΝΟΕΙΔΩΝ 2